CAR T细胞治疗对系统性红斑狼疮患者显示出希望
CAR T-cell therapy shows promise for patients with lupus
一项系统回顾分析了243名系统性红斑狼疮患者接受CAR T细胞治疗的安全性和有效性,结果显示治疗后疾病活动度显著降低,且自体疗法与狼疮肾炎患者的疗效更佳。
系统回顾显示CAR T细胞治疗可显著降低系统性红斑狼疮患者的疾病活动度,为未来研究和临床实践提供依据。
For patients with systemic lupus erythematosus (SLE), chimeric antigen receptor T-cell (CAR T-cell) therapy is associated with consistent reductions in disease activity, according to research presented at the annual meeting of the American College of Rheumatology (ACR Convergence 2026), held from Nov. 6 to 11 in Orlando, Florida.
Alberto Nordmann-Gomes, M.D., from Boston University Medical Center, and colleagues conducted a systematic review of all clinical studies assessing safety and/or efficacy outcomes for CAR T-cell therapy in SLE. Data were included from 31 studies, with a combined population of 243 participants. All studies included patients with refractory SLE who had failed two or more immunosuppressants.
The researchers found 12 patients (5%) reported immune effector cell-associated neurotoxicity syndrome and 11 (5%) developed severe infections. Twenty-two patients (9%) reported prolonged hematologic toxicity. The mean SLE disease activity index (SLEDAI) decreased from 13.0 at baseline to 5.8 after one month, 3.1 after three months and 2.2 after six months of therapy.
Compared with allogeneic therapies and patients without renal involvement, autologous therapies and the presence of lupus nephritis (LN) were associated with a steeper decline in SLEDAI over time (β = 0.43 and 0.35, respectively). Autologous therapies were independently associated with a higher likelihood of achieving an SLEDAI of 0 at last follow-up compared with allogeneic therapies in analyses adjusted for sex, LN status and CAR T-cell target (hazard ratio, 2.33).
"These encouraging findings may help inform patient selection for future studies and, ultimately, clinical practice," senior author Anca D. Askanase, M.D., M.P.H., from the Hospital for Special Surgery in New York City, said in a statement.
Two authors disclosed ties to the biopharmaceutical industry.
More information
Abstract: Alberto Nordmann-Gomes et al., CAR-T cell Therapy in SLE: A Pooled Analysis, presented at the ACR Convergence 2026 conference
Clinical categories
Who's behind this story?
Lisa Lock
BA art history, MA material culture. Former museum editor, paramedic, and transplant coordinator. Editing for Science X since 2021. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
© 2026 HealthDay. All rights reserved.
Citation: CAR T-cell therapy shows promise for patients with lupus (2026, November 16) retrieved 16 November 2026 from https://medicalxpress.com/news/2026-11-car-cell-therapy-patients-lupus.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com